mirodenafil
Sign in to saveMirodenafil is a PDE5 inhibitor used to treat erectile dysfunction. Developed by SK Chemicals Life Science, mirodenafil is marketed in Korea under the brand name Mvix, offered both as tablets (50 mg and 100 mg) and as orally dissolving films (50 mg).
Research
67 papers- Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature.The world journal of men's health · 2014
- Mirodenafil improves cognitive function by reducing microglial activation and blood-brain barrier permeability in ApoE4 KI mice.Frontiers in aging neuroscience · 2025
- Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions.Alzheimer's research & therapy · 2022
- Mirodenafil ameliorates skin fibrosis in bleomycin-induced mouse model of systemic sclerosis.Animal cells and systems · 2021
- A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction.Therapeutic advances in urology · 2016
via PubMed
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Mirodenafil is a PDE5 inhibitor used to treat erectile dysfunction. Developed by SK Chemicals Life Science, mirodenafil is marketed in Korea under the brand name Mvix, offered both as tablets (50 mg and 100 mg) and as orally dissolving films (50 mg).
Despite several clinical trials having been conducted, mirodenafil has not been approved for use in the United States by the US Food and Drug Administration.
Excerpted from Wikipedia’s “mirodenafil” article, available under the CC BY-SA 4.0 licence.